May 06, 2026

Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis

Caris MI Clarity leverages AI to transform how recurrence risk is understood and applied in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer IRVING, Texas, May 5, 2026 /PRNewswire/ -- Caris Life Sciences®...

recent articles

AUSTIN, Texas-- (BUSINESS WIRE) -- Remarkable things are happening as the nation’s medical laboratories and anatomic pathology groups answer the challenges of the COVID-19 pandemic and the need for ever-greater numbers of SARS-CoV-2 tests....

A reliable and intelligent digital pathology solution needs image analysis toolset that helps pathologists to trustfully and accurately assess whole tissue slide images. OptraSCAN’s completely automated PD-L1 image analysis evaluates...

July 9, 2020 . Surgeon at Rush is first to use augmented reality imaging during minimally invasive spine surgery Until now, to perform a minimally invasive surgery or other minimally invasive procedures, a physician would...

It's all about location: Novel prognostic models derived from spatial analysis of the tumor-immune interface 29 July 2020 | 16.00 (London), 11:00 (New York), 08:00 (San Francisco) Duration: 75 minutes Biological interactions...

OR

platinum partners

gold partners

Silver Partners

Media Partners